Water accumulation in the heart is important in ischemia-reperfusion injury and operations performed by using cardiopulmonary bypass, with cardiac dysfunction associated with myocardial edema being the principal determinant of clinical outcome. As an initial step in determining the role of aquaporin (AQP) water channels in myocardial edema, we have assessed the myocardial expression of AQPs in humans, rats, and mice. RT-PCR revealed expression of AQP-1, -4, -6, -7, -8, and -11 transcripts in the mouse heart. AQP-1, -6, -7, and -11 mRNAs were found in the rat heart as well as low levels of AQP-4 and -9. Human hearts contained AQP-1, -3, -4, -5, -7, -9, -10, and -11 mRNAs. AQP-1 protein expression was confirmed by Western blot analysis in all three species. AQP-4 protein was detected in the mouse heart but not in the rat or human heart. To determine the potential functional consequences of myocardial AQP expression, water permeability was measured in plasma membrane vesicles from myocardial cells of wild-type versus various AQP knockout mice. Water permeability was reduced by AQP-1 knockout but not by AQP-4 or AQP-8 knockout. With the use of a model of isolated rat heart perfusion, it was found that osmotic and ischemic stresses are not associated with changes in AQP-1 or AQP-4 expression. These studies support a possible functional role of AQP-1 in myocardium but indicate that early adaptations to osmotic and ischemic stress do not involve transcriptional or posttranslational AQP-1 regulation. aquaporin knockout; cardiac myocyte; cardiopulmonary bypass OUR INTEREST IN CARDIAC AQUAPORINS (AQPs) stems from the recognition that myocardial edema is associated with a significant reduction in cardiac performance in a number of clinically important situations. Ischemia and reperfusion are associated with the development of myocardial edema, with expansion of both interstitial and cellular compartments. The resulting systolic and diastolic dysfunctions are the most important prognostic factors in patient survival after an acute ischemic event or "planned" ischemia, as occurs during cardiac surgery. Procedures involving cardiopulmonary bypass bring additional osmotic stress due to hemodilution and increased vascular permeability (32, 40, 42 
OUR INTEREST IN CARDIAC AQUAPORINS (AQPs) stems from the recognition that myocardial edema is associated with a significant reduction in cardiac performance in a number of clinically important situations. Ischemia and reperfusion are associated with the development of myocardial edema, with expansion of both interstitial and cellular compartments. The resulting systolic and diastolic dysfunctions are the most important prognostic factors in patient survival after an acute ischemic event or "planned" ischemia, as occurs during cardiac surgery. Procedures involving cardiopulmonary bypass bring additional osmotic stress due to hemodilution and increased vascular permeability (32, 40, 42) .
AQPs facilitate movement of water by increasing membrane water permeability, increasing water flux in response to osmotic gradients (reviewed in Ref. 16 ). Multiple lines of indirect evidence have suggested the involvement of AQPs in water movement in the heart. Studies of isolated perfused rabbit heart (14) suggest that interendothelial cell clefts account for twothirds of water movement across the capillary bed and into the interstitial space, with one-third passing through a possible water channel pathway (15) that may involve AQP-1 in cardiac endothelial cells (3) . Measurement of osmotically induced changes in cell volume by videomicroscopy in single cells has suggested the involvement of AQPs in water transport in guinea pig and rat heart cells (36, 37) , based on water transport rates and the inhibitory effect of Hg 2ϩ , a nonspecific, although toxic, AQP inhibitor. However, similar techniques using rabbit ventricular cardiomyocytes (44) suggested that membrane diffusion rather than water channels was the predominant path of water movement. In the unusual circumstance in the heart where there is an outwardly directed osmotic gradient, as occurs during sepsis and after cardiopulmonary bypass, endothelial AQPs are proposed to be primarily responsible for the movement of water out of the interstitial space and into capillaries (15) . In several noncardiac tissues, such as brain (28, 29, 39) and cornea (47) , the involvement of AQPs in the development and resolution of tissue edema has been demonstrated by comparative phenotype studies using knockout mice, providing a rational basis for postulating a role of AQPs in cardiac edema.
There is evidence for expression of AQPs in the heart (reviewed in Ref. 5 ), including AQP-1 expression in endothelium (9, 35) and myocytes (1, 38) of cardiac tissue. Human (20) , rat (11, 13) , and mouse (34) hearts all contain AQP-7 transcript. Low levels of AQP-11 expression were seen by Western blot analysis in the mouse heart (33) . For other AQPs, reports differ, depending on the species examined and techniques used. AQP-4 is generally thought to be absent from ventricular myocardium based on rat studies (6, 7, 10, 46) . However, AQP-4 mRNA has been detected in the human heart (2, 51) . Northern blot analysis of the mouse heart revealed expression of a truncated AQP-4 transcript only (27) . Northern analysis did not detect mRNA for AQP-8 in the rat heart (12, 18) , although a single report showed AQP-8 immunostaining in this species (4) .
The significance of cardiac AQP expression is not currently known. In this study, we characterized AQP expression at baseline in human, rat, and mouse ventricular tissue. Knockout mice were used as controls. We demonstrate the expression of multiple AQPs at transcript level but corresponding protein expression of AQP-1 and AQP-4 only. In addition, we note species differences in expression of AQP-4 protein, which is present at high levels only in the mouse heart. Functional studies demonstrate that AQP-1 facilitates water transport in vitro but that osmotic stress does not involve the regulation of cardiac AQP-1 transcript or protein.
MATERIALS AND METHODS
Human heart and skeletal muscle specimens. The Human Ethics Committee at Children's Hospital at Westmead approved the use of tissue for this study. Human ventricular myocardium was obtained fresh from the operating theater. Tissue normally discarded as part of corrective surgery for children with structural heart disease was used. Ventricular myocardium was most commonly obtained from the right ventricular outflow tract in children undergoing repair for tetralogy of Fallot. Samples from left ventricular (LV) outflow tract and interventricular septum were also available. The tissue was obtained while the patient was on cardiopulmonary bypass after cardioplegic arrest of the heart. Specimens were immediately frozen in liquid nitrogen after resection, with a warm ischemia time of ϳ30 s. Additional cardiac tissue was obtained from donor hearts that were not used for transplantation. Human skeletal muscle was obtained from a bank of tissue that included muscle with normal histology derived from children undergoing amputation for osteosarcoma.
Rat and mouse tissues. The Animal Ethics Committee at Children's Hospital at Westmead approved the use of tissue for this study. Heart and skeletal muscle was harvested from adult Wistar rats and CD1 wild-type, AQP-1 knockout (Ϫ/Ϫ) (24), AQP-4 Ϫ/Ϫ (23), and AQP-8 Ϫ/Ϫ (53) mice under deep anesthesia. Organs were removed and immediately frozen in liquid nitrogen.
Cardiac myocyte preparations. Primary cultures of cardiac myocytes were prepared from the hearts of neonatal Wistar rats by using the Worthington Cardiomyocyte Isolation System (Worthington Biochemical). Cells were prepared from 2-day-old rats following the manufacturer's instructions. The cells were plated onto plastic culture dishes coated with Type IV Collagen (Sigma) at 7.5 g/ml and harvested at various times between 0 and 4 days of culture. Spontaneous beating of the cells was observed from day 1 of the culture. Isolation and culture of cardiac myocytes using this method produces cultures that are Ͼ90% pure, with the major cellular contaminant being fibroblasts (49) .
Subcellular fractionation. Mitochondrial and sarcolemmal membrane fractions were prepared from wild-type mouse skeletal muscle and heart by using OptiPrep gradients (Axis-Shield, Oslo, Norway) following the manufacturer's methods. Fresh tissue was finely minced and then dispersed in ice-cold buffer [250 mM sucrose, 10 mM HEPES (pH 7.4), 1 mM EDTA, and protease inhibitor cocktail] with a dounce homogenizer. Nuclei and whole cells were removed by centrifugation at 700 g for 10 min (ϫ2). The supernatant was then centrifuged for 10 min at 16,000 g to produce a mitochondrial pellet. The supernatant of this spin was retained as the cytoplasmic/membrane fraction. The mitochondrial pellet was washed twice with homogenization buffer. Each fraction was separately added to 20% iodixanol in homogenizing buffer and centrifuged at 300,000 g for 2 h at 15°C to produce a continuous gradient. Fractions were retained, and the membranes were concentrated with further centrifugation at 100,000 g for 30 min. Proteins were solubilized in an equal concentration of 5ϫ SDS sample buffer [240 mM Tris ⅐ HCl (pH 6.8), 6 mM EDTA, 6% SDS, 0.01% bromophenol blue, and 3% mercaptoethanol] before Western analysis was performed.
Western blot analysis. For Western analysis of whole cell lysates, frozen tissue was homogenized in ice-cold lysis buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP-40, and 1 mM PMSF] containing protease inhibitor cocktail (Sigma-Aldrich) using a dounce homogenizer on ice. The homogenate was briefly spun at 1,000 g to pellet cell debris. Protein concentrations were determined with BioRad protein assay dye reagent concentrate (Hercules). The homogenates were mixed with an equal volume of 5ϫ SDS sample buffer before being loaded onto 12% SDS-PAGE gels.
Electrophoresis was followed by transfer to polyvinylidene fluoride Immobilon-P membranes (Millipore Australia, Sydney, NSW, Australia). Membranes were blocked and then incubated with AQP-1 (AQP11-A, 1:1,000 dilution, Alpha Diagnostic, San Antonio, TX), AQP-3 (sc-9885, 1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), AQP-4 (sc-9888, 1:1,000 dilution, Santa Cruz Biotechnology), AQP-5 (1:500 dilution, Merck), AQP-7 (sc-28625, 1:500 dilution, Santa Cruz Biotechnology), mitochondrial porin (1:3,000 dilution, Molecular Probes, Invitrogen), ␤-dystroglycan (1:250 dilution, Novocastra, Newcastle Upon Tyne, UK), cardiac/skeletal actin (5c5, 1:3,000 dilution, Sigma-Aldrich), or vascular endothelial (VE)-cadherin (sc-6458, 1:1,000 dilution, Santa Cruz Biotechnology) antibodies. Secondary antibodies were horseradish peroxidase-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology), donkey anti-rabbit IgG (Amersham Biosciences), or sheep anti-mouse IgG (Amersham Biosciences), and the signal was visualized using enhanced chemiluminescence (Amersham Biosciences).
Immunofluorescence. Cryosections 8-m thick were fixed with 3% formaldehyde in PBS, washed, and incubated in blocking buffer (PBS containing 2% serum). AQP-4 (sc-20812; 1:50 dilution, Santa Cruz Biotechnology), AQP-1 (AQP-11-A, 1:1,000 dilution, Alpha Diagnostic), or ␣-sarcomeric actinin (EA-53, 1:400 dilution, Sigma) antibodies were applied for 1 h. Samples were washed and then incubated with Cy3-conjugated donkey anti-goat or donkey anti-rabbit IgG (1:250 dilution, Jackson ImmunoResearch, West Grove, PA). Samples were washed and mounted by using Shandon Immu-mount.
Tissues used for semithin sections and dual labeling were processed according to Griffiths et al. (8) , with modifications. Tissues were fixed in 4% formaldehyde solution for 30 min before being transferred to 20% sucrose-polyvinylpyrrolidone solution for overnight infiltration. Samples were subsequently frozen in liquid nitrogen. Semithin sections of 0.5-1 m were cut by using a Leica Ultracut UCT ultramicrotome equipped with a Leica EM FC6 cryochamber at Ϫ60°C. Sections were labeled with AQP-1 and Alexa Fluor 488-conjugated donkey anti-rabbit IgG (Molecular Probes, Invitrogen). Colabeling was performed with fluorescein-conjugated isolectin B4 (20 g/ml, Vector, Burlingame, CA) to identify endothelial cells.
RT-PCR. Total RNA was extracted from tissues using Tri Reagent (Molecular Research Center, Cincinnati, OH), followed by cDNA synthesis using oligo dT 15 and reverse transcriptase (Superscript III, Invitrogen). PCR amplifications of cDNA were performed using Taq DNA polymerase (Invitrogen). RNA from tissues known to express each AQP was included as positive controls. Negative controls included no-RT controls in which reverse transcriptase was omitted and there were no template controls in the PCR. All were appropriately negative. Primer sequences for rat AQP-1 to -9 and AQP-11 and human AQP-1 to -11 have been published previously (45) . These and the mouse primers used to screen for AQP transcript are listed in Table 1 .
Quantitative RT-PCR was performed with Lux primers (Invitrogen) for rat AQP-1 (5Ј-CAACGTGTGTGGGAGCCATCG[JOE]TG-3Ј; 5Ј-CCAGGTCATTTCGGCCAAG-3Ј), AQP-4 (5Ј-CACTTA-GAGGCGGTGGGGTAAG[JOE]G-3Ј; 5Ј-TTGAGTCCAGACGC-CTTTGA-3Ј), and 18S (5Ј-GACCTGCCGAGATTGAGCAATAA-CAGG[FAM]C-3Ј; 5Ј-GTAGGGTAGGCACACGCTGAG-3Ј) using the Platinum PCR SuperMix-UDG kit. All samples were run in duplicate. AQP levels were quantified during 45 cycles by using a Corbett Research Rotor-Gene RG 3000A (Mortlake, Victoria, Australia), and analysis was performed by using Rotor-Gene Real Time Analysis Version 6.0 (Corbett Research). mRNA levels were quantified by using 18S rRNA to normalize the raw AQP-1 and AQP-4 signals.
Water permeability measurements. Hearts from three mice were pooled and homogenized, and membrane fractions were purified by centrifugation through a discontinuous sucrose gradient as described previously (50) . Membrane fractions were pelleted, resuspended at ϳ1 mg protein/ml in PBS and passed 10 times through a 27-gauge needle. Stopped-flow measurements of vesicle osmotic water permeability were carried out on a Hi-Tech Sf-51 instrument with measurements repeated 5-10 times per group and repeated in two independent experiments. Membrane vesicles were subjected to a 140 mosM osmotic gradient by mixing with an equal volume of 280 mM mannitol in PBS. The kinetics of decreasing vesicle volume was measured from the time course of 90°scattered light intensity at 530 nm. The data were fitted to a single exponential function. The osmotic water permeability coefficient (P f) was calculated as described previously (48) .
Isolated heart perfusion and ischemia. Rats were anesthetized with inhaled isoflurane-oxygen mixture and injected with 0.5 ml of heparin into the renal vein. A thoracotomy was performed, and the hearts were rapidly excised and plunged into ice-cold Krebs-Henseleit perfusate solution (in mM: 118 NaCl, 25 NaHCO 3, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4, 11 glucose, and 1.2 CaCl2). Baseline control hearts (no perfusion) were processed immediately after removal from the animal. For perfused hearts, the aorta was cannulated, and the hearts were perfused via the ascending aorta with the use of a Langendorff apparatus (Radnoti Glass Technology, Monrovia, CA) at a constant pressure of 80 mmHg. The perfusate was gassed with 95% O 2-5% CO2 and maintained at 37°C. Thebesian vein drainage was vented with a fine cannula placed through the LV apex. The left atrial appendage was removed, and a latex balloon was placed in the left ventricle via the atrium. The balloon was connected to a pressure transducer (Capto, Skoppum, Norway) and filled with saline to produce an end-diastolic pressure of 5 mmHg. Measurements of LV developed pressure (LVDP; systolic and diastolic), contractility (maximum change in LVDP over time), and heart rate were collected online in real time (PowerLab ADInstruments, Sydney, NSW, Australia).
Hearts were first stabilized for 20 min and processed immediately after this time to produce the 20-min control group. An additional control group was produced by maintaining perfusion for an additional 100 min. Hearts in the ischemic treatment group received 20 min of stabilization perfusion, followed by 20 min of zero-flow ischemia and 70 min of reperfusion. Individual hearts were only accepted if the intrinsic heart rate was above 200 beats/min and achieved Ͼ100 mmHg systolic pressure within 20 min of perfusion. The 2-h control animals demonstrate stability of the model; however, meaningful analysis after this point is limited by the inevitable development of cardiac edema.
Statistical analysis. Data are expressed as means Ϯ SE. For physiological data obtained from Langendorff experiments, values were averaged over 10-min epochs ending at the specified time point. Statistical significance was determined by analysis of variance with repeated measures. SPSS for Windows (version 11.5) was used for analysis. Analysis of variance was also used for analysis of densitometry and real-time PCR experiments.
RESULTS

Species variation in AQP expression.
A systematic screen was conducted to determine which AQPs are expressed in the hearts of mice, rats, and humans. Comparison of expression patterns revealed AQP-1, -4, -7, and -11 transcript in the hearts of all three species. RT-PCR of total RNA from mouse heart revealed transcript for AQP-1, -4, -6, -7, -8, and -11 (Fig. 1) . The expression profile for the rat heart showed overlap with the Table 1 . Primers for AQP screen
AQP, aquaporin; F, forward; R, reverse. RNA was extracted from mouse, rat, and human heart specimens and purified rat cardiomyocytes (CM). It was then subjected to RT-PCR amplification for the AQPs detailed in Table 1 . Results shown are representative of 3 individuals of each species and are representative of 3 independent sets of experiments.
Note that rat and cardiomyocyte AQP-10 lanes are empty, because AQP-10 has been shown to be a pseudogene in this species.
mouse heart, with transcript detectable for AQP-1, -6, -7, -9, and -11 ( Fig. 1) . AQP-4 mRNA was detectable in some rat heart samples but only at low levels compared with the positive controls of skeletal muscle and brain (data not shown). To assess the contribution of nonmyocyte sources of AQP expression, cultured rat neonatal cardiomyocytes ("CM" in Fig. 1 ) were also screened, demonstrating mRNA for AQP-1, -3, -4, -5, -7, and -11. Human hearts contained transcript for AQP-1, -3, -4, -5, -7, -9, -10, and -11 ( Fig. 1) . AQP-1 and AQP-4 protein is detected in whole cell lysates of cardiac muscle. Immunoblot analysis was done to determine whether the AQP mRNAs detected produce measurable protein. AQP-1 expression was seen as a 28-kDa nonglycosylated band and a diffuse ϳ40-kDa glycosylated band in the heart ("H" in Fig. 2A ) and skeletal muscle ("M" in Fig. 2A ) of all species. Specificity of the AQP-1 antibody was demonstrated by the absence of specific immunostaining in the heart and muscle of AQP-1 Ϫ/Ϫ mice ( Fig. 2A) . Western blot analysis of AQP-4 revealed a nonspecific protein band at ϳ34 kDa that was in all heart ("H" in Fig. 2B ) and muscle ("M" in Fig. 2B ) samples, including AQP-4 Ϫ/Ϫ mice (Fig. 2B ). Brain ("B" in Fig. 2B ) acted as a positive control for AQP-4 because it contains abundant AQP-4 protein. Two micrograms of brain whole cell lysate contained readily detectable AQP-4 protein for both rats and wild-type mice with no signal in brain homogenate of AQP-4 Ϫ/Ϫ mice (Fig. 2B) . With the use of this band as a size reference to demonstrate the specific detection of AQP-4, protein was demonstrated in skeletal muscle of humans, rats, and mice but only in the heart in mice (Fig. 2B) . When large amounts (Ͼ40 g) of protein were loaded, AQP-4 protein could be detected in some human heart samples but not in rat hearts (data not shown).
Analysis of human, mouse, and rat heart samples did not detect AQP-3, with kidney as positive control (Fig. 2C) . Other organs known to lack AQP-3 expression and included as negative controls were testis, liver, and lung (Fig. 2C) . No signal was seen in human or mouse hearts for AQP-5, with lung homogenate as positive control (Fig. 2D) . The AQP-5 antibody cross-reacted with a minor, nonspecific band in the mouse heart and rat kidney that was larger than the 29-kDa AQP-5 (Fig. 2D ). AQP-6 mRNA was seen in mouse and rat hearts in our screen but not in purified rat cardiac myocytes. AQP-6 protein has been demonstrated in intracellular vesicles in kidneys (56) . However, its water permeability is low and its function is presently unclear, so AQP-6 was excluded from further analysis. AQP-7 is highly expressed in adipose tissue so the presence of transcript may be a contaminant. Western and immunohistochemical analysis to test this were attempted but were not informative as the commercially available AQP-7 antibodies are poor (data not shown). Similarly, the available AQP-8 and AQP-9 antibodies did not produce specific banding on Western blots, precluding analysis of protein expression (data not shown). No antibodies are commercially available for AQP-11. Ϫ/Ϫ ) mouse, and mouse brain (B) contains levels of AQP-1 that are undetectable under these conditions. B: AQP-4 is expressed in muscle of all three species. AQP-4 protein is easily detectable in wild-type (WT) mouse heart but not human or rat heart. No AQP-4 signal is present in AQP-4 Ϫ/Ϫ mouse tissue, but nonspecific bands are noted. Brain (B) acts as a positive control for AQP-4, demonstrating high levels of expression. Twenty micrograms protein (heart and muscle) or 2 g protein (brain) were loaded per lane. C: AQP-3 protein is known to be expressed in kidney and is seen as a positive band on Western blot. No AQP-3 protein is detectable in other organs, including heart. D: AQP-5 expression is not apparent in human or mouse heart or the negative control rat kidney. Whole rat eye does not contain detectable AQP-5 protein, whereas rat lung acts as the positive control to demonstrate AQP-5 expression. Analysis is representative of 3 individuals of each species for all Western blots shown and are representative of 3 independent sets of experiments. E: cardiac myocytes were isolated from whole hearts and cultured for 0 -4 days. Analysis was performed on all culture days with similar results, and the results are representative of 2 independent sets of experiments. Shown is a 3-day culture. Enrichment of the culture is demonstrated by high levels of cardiac actin relative to vascular endothelial (VE)-cadherin. In contrast, heart and muscle contain a greater proportion of VE-cadherin relative to cardiac or skeletal actin. Liver (L) contains vascular tissue but not cardiac or skeletal actin. AQP-1 is expressed by cardiac myocytes as well as being shown in whole organ preparations.
AQP-1 protein is expressed by cardiac myocytes. RT-PCR
screening revealed the presence of AQP-1 transcript in rat cardiac myocytes. Endothelial AQP-1 likely contributes to AQP-1 protein, which is evident in whole heart samples. Although we (1) and others (38) have reported myocyte AQP-1 expression, we sought to confirm this using purified cardiomyocytes.
Cardiac myocytes were purified and cultured from neonatal rat hearts to reduce the signal derived from other cells present in whole heart, in particular, endothelial cells. Myocyte enrichment was confirmed by comparative Western analysis for the endothelium-specific VE-cadherin and the myocyte-specific cardiac/skeletal actin (Fig. 2E) . High levels of cardiac actin and barely detectable levels of VE-cadherin (Fig. 2E ) demonstrated a predominance of cardiac myocytes in the purified sample. By contrast, whole hearts contained a much greater proportion of VE-cadherin to cardiac actin (Fig. 2E) . AQP-1 transcript was present in cardiac myocyte cultures, providing evidence for myocyte-derived expression in addition to the known endothelial expression.
Distribution of AQP-1 and AQP-4 in the heart. AQP expression was visualized by immunohistochemical staining (IHC). AQP-1 was highly expressed in vascular endothelial cells in skeletal (Fig. 3A) and cardiac (Fig. 3C ) muscle. Specificity of staining was demonstrated by absence of signal in tissues from AQP-1 Ϫ/Ϫ mice (Fig. 3, B and D) . AQP-1 expression was confirmed to be endothelial by colocalization with isolectin B1, an endothelium-specific marker (Fig. 3I) . Nonspecific staining of skeletal myofibers (Fig. 3B) is noted in knockout tissue when viewed at high exposures, but this is not evident in the cardiac sections (Fig. 3D) .
AQP-4 IHC revealed myocyte plasma membrane localization in skeletal muscle (Fig. 3E ) that is consistent with previous reports (6) . Mouse hearts also contained AQP-4 protein with a cardiomyocyte membrane distribution (Fig. 3G) . Staining of skeletal muscle (Fig. 3F) and heart (Fig. 3H ) from AQP-4 Ϫ/Ϫ mice was negative, confirming that the immunoreactivity seen in wild-type tissue was specific for AQP-4. Cardiac myocytes were highlighted by staining with the marker ␣-actinin to demonstrate that the AQP-4 signal was present in the myocyte membrane and not that of other cells in the heart (Fig. 3J) .
IHC staining of heart and muscle with the use of the AQP-4 antibody sc-9888 (Santa Cruz Biotechnology) revealed the expected membrane localization and an additional intracellular signal in the myocytes (data not shown). We investigated this further by preparing subcellular fractions of mouse heart and skeletal muscle containing different organelles and performing Western analysis of the protein obtained from these fractions. The fraction enriched for plasma membrane was demonstrated with the marker ␤-dystroglycan, with both AQP-1 and AQP-4 proteins seen in this fraction (Fig. 4) . Neither AQP was localized to fractions containing intracellular organelles, including the mitochondrial fraction marked by the presence of mitochondrial porin (Fig. 4) . Thus AQP-1 and AQP-4 protein is present at the plasma membrane and not in appreciable quantity in intracellular organelles.
AQP-1 is the dominant functional AQP in mouse heart. AQP-1 and -4 were detectable at the transcript level in the hearts of humans, rats, and mice and at the protein level in the mouse heart. We tested the functional relevance of AQP-1 and -4 using membrane vesicle preparations from the hearts of wild-type mice. AQP-8 was also tested as an additional pure water pore that is expressed in mouse hearts but for which Western analysis could not be performed because of poor antibodies. Comparison was made between preparations derived from the hearts of wild-type, AQP-1
, AQP-4 Ϫ/Ϫ , and AQP-8 Ϫ/Ϫ mice. The rate of osmotic equilibration (Fig. 5A ) and deduced water permeability (Fig. 5B) for plasma membranes prepared from wild-type, AQP-4
Ϫ/Ϫ
, and AQP-8 Ϫ/Ϫ mice were consistent with the presence of a functional AQP. There was a small but significant reduction in water permeability in cardiac vesicles from AQP-1 Ϫ/Ϫ mice (Fig. 5, A and  B) . Pretreatment of vesicle preparations with the AQP-inhibitor HgCl 2 reduced the permeability to that of AQP-1 Ϫ/Ϫ samples (Fig. 5, A and B) , further supporting AQP-1-mediated water movement.
Ischemia-reperfusion injury does not induce acute regulation of AQP-1 or AQP-4 expression.
Acute regulation of AQP expression has been demonstrated in other organ systems, including the brain (29) . This was tested in isolated rat hearts by using a Langendorff-based model of ischemia and reperfusion. Four treatment groups were compared with six animals in each group; baseline (hearts excised and not perfused), 20-min perfusion controls, 120-min perfusion controls (without ischemia), and 20-min perfusion/20-min ischemia/70-min reperfusion. Heart function was assessed as the LVDP measured at systole (Fig. 6A) and diastole (Fig. 6B) . Ischemic insult did not affect the systolic LVDP (Fig. 6A ) but resulted in a significant increase in diastolic LVDP during the reperfusion phase; P ϭ 0.002 (Fig. 6B) . This increase in diastolic pressure confirms that the hearts tested suffered a significant ischemic insult. Other indexes of heart function, including heart rate and contractility, recovered to control levels in ischemic hearts during the reperfusion phase (data not shown). AQP-1 and AQP-4 mRNA and protein levels were measured by quantitative RT-PCR and Western blotting, respectively. AQP-1 transcript (Fig. 6D) and protein (Fig. 6C) were not significantly different across all treatment groups. No AQP-4 protein was evident in the hearts, regardless of treatment (data not shown). Although AQP-4 transcript was detectable, it did not reach the amounts measured in skeletal muscle and so was considered not to be physiologically relevant (data not shown).
DISCUSSION
Maintenance of a normal osmotic environment in the heart involves water and solute movements among cellular, interstitial, and blood compartments. Under normal conditions, this is mostly affected by changes in blood osmolality, whereas under pathological conditions, dysfunction of myocardial cell solute transporters and increased capillary leakiness contribute to myocardial edema. Myocardial edema impairs the contractile function of the heart and is a major contributor to the morbidity and mortality associated with myocardial ischemia and cardiac surgery. The heart is remarkable for its high capillary density and regulation of nutrient flow to avoid impairment in cellular metabolism. The purpose of this study was to define the expression pattern and water transport functions of AQPs in the hearts of mice, rats, and humans. Because AQP-4 has been shown in the brain to play a major role in the development and resolution of cerebral edema caused by cellular (cytotoxic) and vascular leak (vasogenic) mechanisms (28), we postulated that AQP(s) in myocardial cells may be involved in clinically relevant cardiac edema. Despite the expression of transcripts for multiple AQPs in the heart by RT-PCR analysis, appreciable protein expression was demonstrated only for AQP-1 and AQP-4. This finding parallels that of several other tissues, such as cholangiocytes and hepatocytes in the liver (30) , where transcripts for many AQPs have been identified, although their physiological relevance is questionable. Although Northern blot analysis of cardiac AQP expression was not performed in this study, others have reported Northern blot data consistent with the RT-PCR data here. This includes the presence of AQP-1 in human and rat hearts (9), AQP-4 in human (51) and mouse (27) hearts, AQP-7 in both human and rat hearts (11, 13, 20) , and AQP-11 in mouse hearts (33) . The species difference in AQP-8 transcript expression described here is supported by separate studies that show the presence of mRNA in mouse hearts (26) and the absence in human (17) and rat (12, 18) hearts. AQPs shown to be absent in the heart by Northern blot analysis include AQP-2 (52) and AQP-5 (19) in mice and AQP-6 in humans (25) .
AQP-1 protein is expressed in the hearts of all three species, and with the use of established methodologies for measuring membrane permeability, AQP-1 was shown to be functional in facilitating osmotic water transport in membranes isolated from wild type mice compared with knockout mice. The AQP-1-dependent percentage of myocardial water permeability of between 20 and 30%, seen in membranes from knockout mice as well as from wild-type mice treated with HgCl 2 , is consistent with the estimated contribution of AQPs to total myocardial water flux determined by Kellen et al. (14, 15) in whole heart experiments, although less than that estimated from isolated cardiomyocytes in studies by Ogura et al. (36, 37) . Importantly, water permeability assessed by Kellen et al. (14, 15) is the net effect of endothelium-and cardiomyocytederived AQPs, whereas that in isolated cells used by Ogura et al. (36, 37) would include only cardiomyocyte-derived AQPs. It is acknowledged that the three different models discussed above are not strictly comparable.
The data here support AQP-1 expression in cardiomyocytes, although at a level considerably lower than that in the vasculature of the heart. AQP-1 expression was found at the sarcolemma in highly enriched rat cardiomyocyte cultures. Although IHC of the mouse heart (Fig. 3, B and C) shows little or no myocyte localization of AQP-1, we (1) and others (38) have previously reported cardiomyocyte expression of AQP-1 in the rat, and the Western analysis shown in Fig. 2E performed by using rat tissue supports this finding. We showed immunolocalization of AQP-1 with t-tubular proteins in the rat heart (1), and Page et al. (38) demonstrated AQP-1 in association with caveolae. Both structures can be considered as sarcolemmal, either the invaginations of the cell membrane into the Z line in the case of the t-tubules or the pinched-off vesicles in the case of caveolae. AQPs appear to be present in isolated cardiac myocytes as demonstrated by measurement of sarcolemmal permeability (37) .
The apparent insensitivity of AQP-1 expression to osmotic stress provided by both isolated perfusion and global ischemia is consistent with our understanding of AQP-1 as a constitutively expressed element of the vascular system. Analyses of in vitro cultured fibroblasts (22) have demonstrated altered AQP-1 expression that occurred over several hours in response to osmotic stress. It is possible that over a longer time frame (Ͼ2 h), changes in mRNA or protein expression may occur; however, this cannot be reasonably achieved with the use of an isolated perfused heart system and will require whole animal models.
Species differences were revealed in cardiac AQP-4 expression. Mouse cardiac and skeletal muscle contains AQP-4 protein, whereas human and rat hearts do not express appreciable protein. A question raised is the physiological relevance, if any, of AQP-4 expression that is specific to the murine heart. Fig. 6 . Ischemic treatment of rat heart and AQP-1 expression. A and B: rat hearts were perfused via the ascending aorta for 20 min and then either processed as controls (■), made ischemic through cessation of perfusate flow (F) for 20 min before reperfusion, or continuously perfused without ischemia ({). Left ventricular systolic pressure (LVP Sys) recovers well after ischemia (A), whereas diastolic pressure (LVP Dias) is significantly increased (P ϭ 0.002) in the reperfusion phase, as expected after a significant ischemic episode. AQP-1 protein expression, measured by Western blotting and normalized to the expression of cardiac actin (C), was not affected by osmotic or ischemic stress. AQP-1 transcript levels were unchanged (D), and AQP-4 transcript was not induced during recovery period.
AQP-4 increases water permeability by a much greater amount than does AQP-1 (55): the faster heart rate and metabolic rate of the mouse may mandate AQP-4 expression. However, it is noted that the permeability of cardiac membrane vesicles was not reduced by AQP-4 deletion. Furthermore, there was no evidence of upregulation of AQP-4 expression in the rat over the observation period after ischemia. Physiologically relevant AQP function can be difficult to distinguish in an in vitro analysis in some cases (43) . On the other hand, the presence alone of an AQP does not provide evidence for physiological relevance, borne out by investigations of AQP-4 in skeletal muscle function (54) . Cardiac and skeletal muscles exhibit many similarities, including the expression of AQP-1 (1) and AQP-4 (54) proteins, but also important differences in resistance to fatigue and choice of metabolic substrate. These differences are relevant to the way each muscle handles water.
We report the presence of AQP-3 and AQP-5 mRNA but the absence of detectable protein in the human heart. The same may be true of AQP-8 in the mouse heart, in that the AQP-8 transcript was easily detected; however, we were unable to satisfactorily assess AQP-8 protein expression using commercial antibodies. At this point, it is not possible to accurately determine the localization or functional significance of AQP-7, -8, -9, or -11 in the heart with antibody methods, and this situation highlights many contemporary issues in AQP research in which antibodies validated with positive and negative controls are not available. The creation of double knockout animals and better-controlled models may be required.
In conclusion, we demonstrate the expression and functional relevance of AQP-1 in the heart. We also show evidence for AQP-1 expression by rat and human cardiac myocytes and AQP-4 by mouse cardiac myocytes. Because only small changes in myocardial water content are associated with significant impairment of cardiac function (21, 31, 41) , detailed examination of myocardial water handling and the role of AQPs may reveal potential avenues for therapeutic intervention.
